产品
编 号：F762345
分子式：C10H14N2O2
分子量：194.23
分子式：C10H14N2O2
分子量：194.23
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 847952-38-9
产品详情
生物活性：
NNZ 2591 is a synthetic analogue of a small peptide of cyclic glycine proline (cGP). NNZ 2591 shows orally active and cross the blood-brain barrier. NNZ 2591 shows neuroprotective after ischemic brain injury. NNZ 2591 improves motor function in a rat model of Parkinson's disease. NNZ 2591 has the potential for the research of ischemic brain injury and angelman syndrome.
体内研究：
NNZ 2591 (30 mg/kg; p.o.) prevented scopolamine-induced memory impairment in rats.NNZ 2591 (2, 20, 100 ng/rat; i.c.v.) shows neuroprotection in rats.NNZ 2591 (3 mg/kg; s.c.; daily for 5 days) completely preventes brain damage and significantly reduces the L/R ratio of time taken to touch to the patch at 5 d after injury in rats.Animal Model:4 months, male young adult Wistar rats.
Dosage:30 mg/kg
Administration:P.o.; 10 min after the (scopolamine) i.p. administration.
Result:Significantly reduced the number of M2AchR positive neurons, significantly reduced the density of synaptophysin in the CA3 and CA4 sub-regions, and altered TH terminal staining in the striatum.
Animal Model:280-310 g adult male Wistar rats.
Dosage:2, 20, 100 ng/rat
Administration:I.c.v.; 2 h after HI injury
Result:Reduced overall tissue damage in the sub-regions of the hippocampus, DG, cerebral cortex and the striatum.
Animal Model:280-310 g adult male Wistar rats.
Dosage:3 mg/kg
Administration:S.c.; daily for 5 days
Result:Significantly reduced the median of tissue damage scores in the CA1-2, CA3 and CA4 sub-regions of the hippocampus, the DG.
NNZ 2591 is a synthetic analogue of a small peptide of cyclic glycine proline (cGP). NNZ 2591 shows orally active and cross the blood-brain barrier. NNZ 2591 shows neuroprotective after ischemic brain injury. NNZ 2591 improves motor function in a rat model of Parkinson's disease. NNZ 2591 has the potential for the research of ischemic brain injury and angelman syndrome.
体内研究：
NNZ 2591 (30 mg/kg; p.o.) prevented scopolamine-induced memory impairment in rats.NNZ 2591 (2, 20, 100 ng/rat; i.c.v.) shows neuroprotection in rats.NNZ 2591 (3 mg/kg; s.c.; daily for 5 days) completely preventes brain damage and significantly reduces the L/R ratio of time taken to touch to the patch at 5 d after injury in rats.Animal Model:4 months, male young adult Wistar rats.
Dosage:30 mg/kg
Administration:P.o.; 10 min after the (scopolamine) i.p. administration.
Result:Significantly reduced the number of M2AchR positive neurons, significantly reduced the density of synaptophysin in the CA3 and CA4 sub-regions, and altered TH terminal staining in the striatum.
Animal Model:280-310 g adult male Wistar rats.
Dosage:2, 20, 100 ng/rat
Administration:I.c.v.; 2 h after HI injury
Result:Reduced overall tissue damage in the sub-regions of the hippocampus, DG, cerebral cortex and the striatum.
Animal Model:280-310 g adult male Wistar rats.
Dosage:3 mg/kg
Administration:S.c.; daily for 5 days
Result:Significantly reduced the median of tissue damage scores in the CA1-2, CA3 and CA4 sub-regions of the hippocampus, the DG.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备